⚠ COVID-19 INFORMATION: Vaccine Information, Other Resources 

Abatacept as GVHD Prophylaxis Phase 2

Official Title: Abatacept as GVHD Prophylaxis Phase 2

This is a phase II multi-center, randomized, double blind, placebo-controlled trial. The investigators are doing this study to see if a new drug, abatacept, can be used together with a calcineurin inhibitor (cyclosporine or tacrolimus) and methotrexate to provide better protection against Acute Graft versus Host Disease (aGvHD) without causing more infections. Funding Source - FDA OOPD
Chaudhury, Sonali, MD

Contact Information:

Sonali Chaudhury, MD

Principal Investigator